Interpleural infusions (24 hr) were given to 14 adults yr) having surgery via right subcostal incisions. Patient-controlled analgesia with morphine was also available for 72 hours following surgery. An infusion of 0.25 % bupivacaine with adrenaline 11400,000 was commenced at 0.1 mllkg/hr at the conclusion of surgery after an initial 20 ml bolus. The 24 hr cumulative morphine dose increased by 62% (P < 0.01) on the second postoperative day after the bupivacaine infusion was ceased, but the pain score did not change. There was no clinical evidence of bupivacaine toxicity although the maximum bupivacaine concentration ranged from 0.74-6.52 mg/I, mean 2.90 (SEM 0.44) mg/I and vascular uptake was rapid in two patients. The concentration of S-bupivacaine was consistently greater than R-bupivacaine (P < 0.05) and total body clearance was less.
Interpleural bupivacaine provides effective analgesia after abdominal surgery, but the long duration of action from single bolus doses that was reported initially has not been confirmed 1-3. Recent studies indicate that continuous infusion of bupivacaine provides better pain control than intermittent bolus doses and that the bupivacaine concentration need not be greater than 0.25070 4 -6 • However, interpleural injection of bupivacaine may result in higher peak plasma concentrations than intercostal injections to achieve the same dermatome blockade and several cases of toxicity have been reported 7 ,8. The peak plasma concentraions after bolus doses can be reduced by the addition of adrenaline 9 ,1O, but if adequate analgesia is to be obtained they may still exceed the 3-4 mg/l that has been associated with seizure activity in humans ll -13 • Experiments in sheep have shown that the R-and S-enantiomers of bupivacaine have different clearances and in an isolated heart preparation the R-enantiomer was found to have greater cardio-toxicityI4, 15 . With continuous interpleural bupivacaine infusion changes in plasma proteins over 24 hours may reduce the unbound fraction of the total bupivacaine as reported following other routes of administration 16,17. Previous studies of the kinetics of interpleural bupivacaine have not measured both the degree of protein binding and separation of the R-and Senantiomers during continuous infusion 4 -6 ,13,17. The aims of the present study were: (1) to demonstrate the efficacy of a 24-hour 0.25% bupivacaine interpleural infusion following hepato-biliary surgery, (2) to derive pharmacokinetic parameters for the two bupivacaine enantiomers and estimate the variability between patients, including that due to protein binding, patient age, weight and sex, (3) to estimate the effects of changes in unbound fraction on the pharmacokinetics.
METHODS
The study was approved by the Board of Medical Research and Ethics Committees of the Royal Melbourne Hospital. Consecutive patients scheduled for abdominal surgery via right upper quadrant incisions were recruited after informed consent was obtained. Patients with a history of pneumothorax, emphysema, recent pneumonia, pleurisy or chronic use of opioids were excluded. Intravenous patientcontrolled analgesia (PCA) was explained on the day prior to surgery and made available to all patients for 72 hours following surgery. The bolus PCA dose was 1 mg morphine in 0.5 ml with a 5 minute lockout interval.
Patients received temazepam (10-20 mg) premedication, induction of anaesthesia with thiopentone and morphine (0.1 mg/kg), and maintenance with isoflurane, 70% nitrous oxide and vecuronium. A 16 gauge interpleural catheter was inserted in the 8th right intercostal space at the conclusion of surgery and prior to reversal of the neuromuscular blockade. With the patient in the lateral position and the endotracheal tube disconnected, a Tuohy needle was advanced with an air-filled lubricated glass syringe attached until the plunger of the syringe dropped. The catheter was then inserted 7-10 cm. After aspiration, an initial 20 ml bolus of 0.25070 bupivacaine with adrenaline 11400,000 was given and an infusion commenced at 0.1 mllkg/hr. PCA with morphine was started as soon as the patient was sufficiently recovered from general anaesthesia.
Postoperative pain was evaluated by verbal scores (scale 0-10) recorded hourly by nursing staff when patients were awake. The number of morphine doses received, the number of demands for analgesia and the respiratory rate were recorded hourly.
Arterial blood samples (5 ml) for bupivacaine assay were taken 0,5,10,20,30,40,60 and 120 minutes after the initial dose from the radial artery catheter left in situ after the procedure. Subsequently, peripheral venous blood samples were taken at 4,8,12,16,20 and 24 hours infusion and at 15,30,60,120 and 240 minutes after termination of the infusion. Samples were centrifuged and plasma stored at -20°C. On the day of study, portions of each sample (plasma, 1 ml) were ultrafiltered using the Micropartition System MPS-l with YM-T membrane (Amicon, Oenver, USA) for 30 min at 1000g and 37°C. The ultrafiltrates were stored frozen.
Bupivacaine enantiomer concentrations were measured using a modified HPLC method l8 . Plasma (l ml) or ultra filtrate containing bupivacaine was made alkaline with 250 J.tl 0.8M NaOH and extracted into 5 ml hexane, along with 100 J.tl lignocaine 10 mg/l as the internal standard, in a polypropylene centrifuge tube. The hexane phase was transfered to a second polypropylene tube, evaporated to dryness under nitrogen at 40°C and reconstituted in 100 J.tl of mobile phase. The mobile phase was 8:92 isopropanol:lOmM K2HP04 at pH 6.3, running through a 100 mm X 4.0 mm CHIRAL-AGP column (ChromTech AB, Norsborg, Sweden) at 0.9 mllmin with detection by UV absorbance at 210 mm. The assay was linear to at least Anaesthesia and Intensive Care, Vol. 22, No. 5, October, 1994 20 mg/l, with detection limits of 0.02 mg/l for each enantiomer, and within-day coefficients of variation of 4.5070 and 4.8% (n = 6) at 1 mg/l for R-and Sbupivacaine respectively.
NONMEM, a nonlinear multiple effects model regression programl9, was used to derive average pharmacokinetic parameters for R-and S-bupivacaine and to estimate the influence of unbound fraction, age, weight and sex on those parameters. The influence of an individual factor on the model was considered according to the following criteria: the difference in -2 log likelihood (the objective function of NONMEM which is approximately Chi-square distributed), the standard errors of the parameter estimates, plots of the residuals and the residual interindividual variability. P<0.005, equivalent to a minimum log likelihood difference of 7.8, was chosen as the minimum improvement in objective function for a factor to be retained in the model in view of the asymptotic nature of the Chi-square approximation 20. Morphine requirements and pain scores were compared by paired t-test and Wilcoxon test respectively.
RESULTS
Interpleural infusions were completed in 14 patients (8 males, 6 females), mean age 55 years (range 29-81 years). All had right upper-quadrant transverse abdominal incisions for surgical procedures including partial hepatectomy, excision of hydatid cysts, distal pancreatectomy, cholecystectomy and biliary bypass. In all cases surgery was more extensive than for simple open cholecystectomy. Liver enzymes were elevated in four patients prior to surgery, but coagulation tests were normal in all patients. After instruction on the day prior to surgery all patients were judged capable of utilising intravenous PCA. The ratio of analgesic doses requested to doses delivered by the infusion device was l.3 (SO 0.3) and lA (SO 0.7) on the first and second postoperative days respectively. The 24 hour cumulative morphine dose increased by 62% (P = 0.01) after the bupivacaine infusion was ceased ( Table 1) . Morphine dosage ranged from 3 mg to 112 mg on the second day despite similarity in the surgical incision used. The average hourly pain score for each day did not change (P=0. 15 ), but on the second postoperative day the pain stimulus would be expected to be decreasing. There was no clinical evidence of bupivacaine toxicity although the 24 hour total bupivacaine concentration ranged from 0.74-6.52 mg/l, mean 2.90 (SE M 0.44) mg/l. In two patients there was an atypical plasma concentration curve that suggested rapid vascular uptake (Figure 1) . Data from the remaining 12 patients, in which there was an initial peak in plasma bupivacaine after the interpleural bolus followed by a progressive increase with the infusion to 24 hours, were used for the pharmacokinetic analysis. The plasma concentrations of S-bupivacaine were greater than Rbupivacaine (P < 0.05) and the ratio did not change significantly during the infusion (Figure 2 ). The ratio of R-and S-bupivacaine was reversed in one patient. That patient did not have abnormal hepatic or renal function and no cause was found. Four hours after the infusion ceased plasma concentrations were still 50070 of the peak and the data was considered insufficient to calculate an elimination half-life.
The unbound bupivacaine plasma profiles were similar to those for the total bupivacaine ( Figure 2 ). However, there was a poor correlation between the total and unbound bupivavcaine concentrations at 24 hours (Pearson correlation coefficient 0.5, Figure 3 ). The unbound fraction also changed from 3.6% (SE M 0.6) at the start of the infusion to 2.0070 (SEM 0.3) at 24 hours (p<0.005).
The NONMEM analysis did not detect any relationship between pharmacokinetic parameters and weight, age or sex (P<0.25 in each case). The pharmacokinetic parameters estimated with NONMEM are shown in Table 2 . A two-compartment model (plus an absorption depot) was preferable to a one-compartment model (P<O.OOl), but a three compartment model could not be fitted to the data. Estimates of the total body clearance of the R-and S-enantiomers are presented because these differed significantly Anaesthesia and Intensive Care, Vo!. 22, No. 5, October, 1994 (P < 0.001), but estimates of central volume, intercompartmental clearance and absorption half-life were similar for the two enantiomers.
Variation between patients was reduced when these parameters were estimated for the free (unbound) bupivacaine (NONMEM -2 log likelihood, Chi-square, P< 0.001). However, coefficients of variation for the interindividual variability ranged from 36% (absorption rate constant) to 74% (steady-state volume) reflecting the large range in plasma bupivacaine concentrations. Averaged pharmacokinetic parameters for total bupivacaine in the twelve patients at the start of the infusion and at 24 hours were obtained by multiplying by the fraction of unbound drug for each enantiomer in each individual at those times ( Table 2 ). The increased plasma binding after 24 hours of infusion reduced the estimates of total body clearance, intercompartmental clearance and steady-state volume. Plasma bupivacaine concentrations during a 48 hour infusion as predicted by the NONMEM analysis in the twelve patients used for the pharmacokinetic analysis are shown in Figure 4 . Further changes in plasma protein binding are not taken into consideration in this prediction. Total bupivacaine would be expected to increase from 2.66 mg/l (SEM 0.40) to 3.62 mg/l (SEM 0.51) during the second 24 hours, although this would be accompanied by an increased separation of the concentrations of the two enantiomers.
DISCUSSION
The cumulative morphine dose for the 24 hours during interpleural infusion in these patients was 50% greater than reported previously for a similar infusion and PCA after cholecystectomy or renal surgery5,6. Pain due to hepatic or pancreatic dissection may be greater than with other types of surgery, or less well controlled by interpleurallocal anaesthesia. However, the PCA parameters also differed, with a much shorter lockout interval in our study (5 versus 25 minutes) and this may influence morphine dosage independent of the pain stimulus. The mean pain score of less than 3 on a scale 0-10 represents a satisfactory result on the first postoperative day after major upper abdominal surgery. Despite some residual interpleural blockade on day 2, there was a significant increase in morphine consumption to maintain a similar pain score, presumably with some decline in the pain stimulus.
Abnormal liver transaminase enzymes were noted preoperatively in four patients, but this did not correlate with high plasma bupivacaine concentrations or ratio of the R-and S-enantiomers. This ratio was reversed in only one patient and no explanation was found. The assay was repeated on stored plasma samples from that patient to exclude laboratory error. bUnbound fraction changed from 3.9 (0.6)070 at t = 0 hr to 2.2 (0.3)070 at t = 24 h in these twelve patients. Mean (SEM).
The individual estimates are from the twelve individual patients studied, whereas the population estimates represent the population from which they were drawn.
The failure to show any predictive value of weight, age or sex suggest that, within the limits of this study, these factors need not be used to determine bupivacaine dose. However, the data lacks patients at the extremes of weight or age range. The atypical plasma profile obtained in two patients, a very high peak following the initial bolus, probably resulted from positioning of the increase with 24 hour interpleural infusion was similar to that reported previously and shown to be due to an increase in alpha I-acid glycoprotein 6 • This contributes to the failure to reach a steady-state plasma concentration by 24 hours. The total body clearance and the apparent steady-state volume decrease because of the change in binding. The two major binding proteins for bupivacaine are alpha I-acid glycoprotein and albumin and its distribution characteristics do not change significantly over a wide range of bupivacaine con centrations 22 • An increase in the total bupivacaine increases the total body unbound fraction mainly due to a decrease in tissue binding. The poor correlation between unbound and total bupivacaine concentrations at 24 hours in the present study was surprising, but probably reflects a wide variation between patients in plasma protein available for binding. At bupivacaine concentrations greater than 2 mg/l, variation in the high capacity, low affinity binding to albumin is important 22 • These variations contribute to the difficulty in predicting the threshold for bupivacaine toxicity in individual patients.
A time-dependent reduction in the clearance of bupivacaine has been suggested previously with epidural infusions and with IV infusion in dogs 21 ,23. Suggested mechanisms are an increased binding to alpha I-acid glycoprotein and a decrease in intrinsic hepatic clearance 2' • However, no change in clearance was found with a 72 hour interpleural infusion". The unbound fraction of bupivacaine was not measured in that study and the authors suggest that the measured constant total plasma bupivacaine concentration may have masked a declining free drug concentration. The mean initial clearance for the two enantiomers in the present study was similar to that reported by Kastrissios et al. for continuous interpleural infusion", or multiple bolus doses' 2 , but declined by 44070 at 24 hours. Our estimate of steady-state distribution volume was reduced to 115 litres at 24 hr, within the range (38-148 litres) of the previous infusion study'7.
The concentrations of bupivacaine recorded in many reports of interpleural analgesia with either bolus doses or continuous infusion suggest a narrow margin of safetyS-12. The scarcity of reports of actual toxicity may be related both to the change in binding and to the greater clearance of the more toxic R-enantiomer as studies in several animal species have shown that the S-enantiomer has less cardiac and central nervous system toxicitylS,24. Our results indicate that the use of patient age, weight or sex in determining the interpleural bupivacaine dose is unlikely to reduce the variability in plasma concentration, although further study at the extremes of age and weight is required.
